D a t a s o u r c e s
In 1995, a registry was established of all large-scale trials that were in progress or in advanced stages of planning.
S t u d y s e l e c t i o n
Studies were selected if there was a randomized comparison between patients allocated to a blood pressure−lowering drug and placebo or to another active antihypertensive agent or to a blood pressure−lowering strategy that had a different intensity. Trials had to have a minimum of 1000 patient-years of follow-up planned and must not have been published before July 1995.
D a t a e x t r a c t i o n
Data were extracted on patient characteristics, discontinuation rates, blood pressure, and major outcomes. Individual patient data or summary data were combined.
M a i n r e s u l t s
Data from 15 trials (74 696 patients, mean age 62 y, 53% men) were included. Combining data from 4 placebo-controlled trials of ACE inhibitors showed that active treatment led to relative reductions of 20% to 30% in stroke, CAD, and major cardiovascular events. Combining data from 2 placebo-controlled trials of CAs showed that active treatment led to relative reductions of 28% to 39% in stroke and major cardiovascular events. Combining data from 3 trials of blood pressure−lowering regimens of different intensity showed that more-intensive strategies led to greater relative reductions of 15% to 20% in stroke, CAD, and major cardiovascular events. Combining data from 3 trials that compared ACE inhibitors with diuretics or β-blockers showed no differences between the agents for any outcome. Combining data from 5 trials that compared CAs with diuretics or β-blockers showed a slightly lower risk for stroke and a slightly higher risk for CAD with CAs (Table) .
C o n c l u s i o n s
In patients with hypertension, diabetes mellitus, coronary artery disease, or renal disease, angiotensin-converting enzyme inhibitors and calcium antagonists are more beneficial than placebo. Calcium antagonists lead to a lower risk for stroke but to a slightly higher risk for coronary artery disease than do diuretics or β-blockers. 
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C o m m e n t a r y
Bottom-line interpretations of these 2 meta-analyses will vary depending on previous beliefs. For methodologic purists and fans of CAs, the data neither prove nor refute the choice of CAs as first-line agents for adults with hypertension or those at high risk for cardiovascular disease. For those of us who are already wary of using CAs as first-line therapy, the data support our practice of avoiding these agents. Many of us, regardless of our previous beliefs, may now question whether we should either begin reserving or using CAs specifically for persons who have high risk for stroke. Such a decision would be premature for at least 2 reasons. First, we cannot reliably determine whether an individual is likely to have a stroke and no cardiac outcomes. Second, the important meta-analyses summarized here are limited and complicated. The meta-analyses have limited power to precisely assess stroke and cardiac outcomes because few large, long-term trials exist that directly compare the effects of different antihypertensive agents. They are complicated because they combine data from trials characterized by either discontinuation of initial antihypertensive drug therapies or the addition of second and third antihypertensive agents. They make comparisons by grouping all drugs within a class together (e.g., CAs) as well as by grouping drugs across classes together (e.g., diuretics and β-blockers). This method is dicey because all antihypertensive drugs have actions other than that of lowering blood pressure, and mechanisms by which a drug lowers blood pressure probably have effects independent of the blood pressure−lowering effect (1) . Moreover, mechanisms of action and effects may vary among antihypertensive drugs within classes as well as across classes.
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Q u e s t i o n
In patients with hypertension, are calcium antagonists (CAs) as first-line therapy superior, equal, or inferior to other antihypertensive drugs for reducing major cardiovascular events?
D a t a s o u r c e s
Studies were identified by searching MED-LINE up to September 2000, the U.S. National Library of Medicine clinical trials database, and the Cochrane Library; by reviewing reference lists of identified articles; and by contacting colleagues.
S t u d y s e l e c t i o n
Studies were selected if they were randomized controlled trials published in peer-reviewed journals that included > 100 patients with hypertension who were allocated to first-line therapy with a CA or other antihypertensive agent and who were followed for ≥ 2 years for the assessment of cardiovascular events.
D a t a e x t r a c t i o n
Data were extracted on drug type and dose, patient characteristics, and main outcomes. Summary data were pooled.
M a i n r e s u l t s 9 trials involving 27 743 patients with about 120 000 person-years of follow-up met the selection criteria. CAs and other antihypertensive agents led to similar reductions in blood pressure. Patients assigned to diuretics, β-blockers, angiotensin-converting enzyme (ACE) inhibitors, or clonidine (n = 15 044) had a lower risk for myocardial infarction (MI), congestive heart failure, and major cardiovascular events than did those allocated to CAs (n = 12 699) (Table) . No statistically significant differences were found for stroke or all-cause mortality (Table) .
C o n c l u s i o n
In patients with hypertension, initial therapy with calcium antagonists leads to higher risks for myocardial infarction, congestive heart failure, and major cardiovascular events than does therapy with other antihypertensive agents.
